Follow
"Although marketed CAR-T therapies have shown transformative efficacy for certain blood cancers, widespread adoption, as well as applicability to solid tumours and autoimmune indications, have been limited by safety, efficacy and operational hurdles. These hurdles include high rates of adverse events such as cytokine release syndrome (CRS), inability to overcome the immunosuppressive microenvironment typically found in solid tumours, and antigen escape and cell exhaustion that reduce durability."
